Paik JM, et al. Sodium-glucose cotransporter 2 inhibitors and nephrolithiasis risk in patients with type 2 diabetes. JAMA Intern Med 2024; 184:265–274. doi: 10.1001/jamainternmed.2023.7660
Anan G, et al. Inhibition of sodium-glucose cotransporter 2 suppresses renal stone formation. Pharmacol Res 2022; 186:106524. doi: 10.1016/j.phrs.2022.106524
Kristensen KB, et al. Sodium–glucose cotransporter 2 inhibitors and risk of nephrolithiasis. Diabetologia 2021; 64:1563–1571. doi: 10.1007/s00125-021-05424-4
Cosentino C, et al. Nephrolithiasis and sodium-glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized controlled trials. Diabetes Res Clin Pract 2019; 155:107808. doi: 10.1016/j.diabres.2019.107808
Cianciolo G, et al. Mineral and electrolyte disorders with SGLT2i therapy. JBMR Plus 2019; 3:e10242. doi: 10.1002/jbm4.10242
Harmacek D, et al. Empagliflozin changes urine supersaturation by decreasing pH and increasing citrate. J Am Soc Nephrol 2022; 33:1073–1075. doi: 10.1681/ASN.2021111515
Bletsa E, et al. Effect of dapagliflozin on urine metabolome in patients with type 2 diabetes. J Clin Endocrinol Metab 2021; 106:1269–1283. doi: 10.1210/clinem/dgab086
Pak CY, et al. Spontaneous precipitation of brushite in urine: Evidence that brushite is the nidus of renal stones originating as calcium phosphate. Proc Natl Acad Sci USA 1971; 68:1456–1460. doi: 10.1073/pnas.68.7.1456
Maalouf NM, et al. Association of urinary pH with body weight in nephrolithiasis. Kidney Int 2004; 65:1422–1425. doi: 10.1111/j.1523-1755.2004.00522.x
Onishi A, et al. A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin. Am J Physiol Renal Physiol 2020; 319:F712–F728. doi: 10.1152/ajprenal.00264.2020
Wiederkehr MR, Moe OW. Uric acid nephrolithiasis: A systemic metabolic disorder. Clin Rev Bone Miner Metab 2011; 9:207–217. doi: 10.1007/s12018-011-9106-6